$IOVA News

Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?

Why Iovance Biotherapeutics Stock Hit 52-Week High

UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7

Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates

Mizuho Maintains Outperform on Iovance Biotherapeutics, Raises Price Target to $11

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Iovance (IOVA) Q2 2026 Earnings Call Transcript

Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $13

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?

Iovance Biotherapeutics, Inc. Q2 2026 Earnings Call Summary

Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $8

Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highlights: Record Revenue and ...

Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next

Iovance Biotherapeutics Q2 Earnings Call Highlights

IOVA Stock Heads For Best Day In Over 6 Years – Buyout Buzz Builds After Blowout Q2

Iovance Biotherapeutics Reports Record Q2 Revenue and Reviews 2026 Outlook on Strong Amtagvi Demand

Iovance: Stock Soars On Q2 Earnings - Critical Data In Melanoma, NSCLC Due September

Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump